传染病检测市场－全球产业规模、份额、趋势、机会和预测（按产品与服务、按技术、按疾病、按最终用户、按地区和竞争细分，2020-2030 年）

2024 年全球传染病检测市场价值为 340.9 亿美元，预计在预测期内将呈现令人印象深刻的成长，到 2030 年的复合年增长率为 7.71%。细菌、寄生虫、病毒和真菌是传染病的病原体。这些疾病的识别和表征属于传染病诊断领域。医生和医疗保健专业人员主要依靠患者的症状和身体检查来检测传染病。他们会进行一系列实验室测试来确定病原体，使医疗保健提供者能够实施适当的医疗治疗。病原体可以透过直接接触、水或食物传播、环境中受感染颗粒的气溶胶化以及透过昆虫（如蚊子）和蜱虫传播。

免疫系统受损的人特别容易受到某些感染。这包括正在接受癌症治疗或近期接受器官移植的人。未接种常见传染病疫苗的人、医护人员以及前往疟疾和登革热等蚊媒病原体高风险地区的人员面临更高的风险。医生会使用各种实验室检查来诊断传染病。全球传染病检测市场在及时诊断和管理各种传染病方面发挥关键作用。随着病毒和细菌感染的日益流行，整个医疗保健系统对快速、准确且易于获取的诊断工具的需求也日益增加。市场包括针对爱滋病毒、肝炎、结核病、流感等疾病以及最近出现的新冠病毒和猴痘等威胁的检测解决方案。

技术进步是关键驱动力，尤其是分子诊断、即时检测和实验室自动化的应用。这些创新缩短了周转时间，提高了敏感度和特异性，并改善了疾病监测。家庭护理和远距诊所等分散式医疗保健场所的扩张进一步刺激了对便携式和易用型检测试剂盒的需求。例如，2024年12月，摩洛哥生物技术公司Moldiag推出了非洲首款本地生产的mpox检测试剂盒，这是加强非洲大陆医疗保健自给自足能力的重要里程碑。这项进展减少了对进口诊断工具的依赖，并增强了区域应对传染病疫情的能力。 Moldiag的倡议标誌着非洲在建立生物技术基础设施和改善及时获取基本诊断解决方案方面取得了关键进展。

关键市场驱动因素

传染病日益流行

主要市场挑战

报销不足

主要市场趋势

即时检验 (POCT)

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球传染病检测市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按产品和服务（分析、试剂盒、试剂、仪器、服务和软体）
  • 按技术（分子诊断、免疫测定、微生物学、其他）
  • 依疾病（肝炎、人类乳突病毒 (HPV)、人类免疫缺乏病毒(HIV)、结核病 (TB)、医院内感染 (HAI)、其他）
  • 按最终使用者（医院和临床实验室、诊断参考实验室、学术/研究机构、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美传染病检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲传染病检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太传染病检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲传染病检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲传染病检测市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第十三章：全球传染病检测市场：SWOT分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

第 16 章：策略建议

第17章调查会社について・免责事项

Global Infectious Disease Testing Market has valued at USD 34.09 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.71% through 2030F. Bacteria, parasites, viruses, and fungi are the causative agents of infectious diseases. The identification and characterization of these diseases fall under the domain of infectious disease diagnostics. Physicians and healthcare professionals primarily rely on patients' symptoms and physical examinations to detect infectious infections. A range of laboratory tests is conducted to determine the causative agents, enabling healthcare providers to administer appropriate medical treatments. Pathogens can be transmitted through direct contact, water or foodborne routes, aerosolization of infected particles in the environment, as well as via insects (such as mosquitoes) and ticks.

Individuals with compromised immune systems are particularly vulnerable to certain infections. This includes those undergoing cancer treatment or recent organ transplant recipients. The individuals who have not been vaccinated against common infectious diseases, healthcare workers, and those traveling to high-risk areas with mosquito-borne pathogens like malaria and dengue fever are at increased risk. Various laboratory tests are employed by doctors to diagnose infectious disorders. The global infectious disease testing market plays a critical role in the timely diagnosis and management of a wide array of contagious illnesses. With the growing prevalence of both viral and bacterial infections, there is a heightened need for rapid, accurate, and accessible diagnostic tools across healthcare systems. The market includes testing solutions for diseases such as HIV, hepatitis, tuberculosis, influenza, and more recently, emerging threats like COVID-19 and monkeypox.

Technological advancements have been a key driver, particularly the adoption of molecular diagnostics, point-of-care testing, and automation in laboratories. These innovations enable quicker turnaround times, increased sensitivity and specificity, and improved disease surveillance. The expansion of decentralized healthcare settings, such as home care and remote clinics, has further spurred demand for portable and easy-to-use test kits. For instance, in December 2024, Moroccan biotech company Moldiag launched Africa's first locally produced mpox test kits, representing a major milestone in strengthening the continent's healthcare self-sufficiency. This development reduces dependence on imported diagnostic tools and enhances regional capacity to respond to infectious disease outbreaks. Moldiag's initiative marks a critical advancement in building Africa's biotechnology infrastructure and improving timely access to essential diagnostic solutions.

Key Market Drivers

Increasing Prevalence of Infectious Diseases

The global infectious disease testing market is experiencing significant growth due to the increasing prevalence of infectious diseases worldwide. The rising prevalence of infectious diseases, particularly tuberculosis (TB), is a key driver of growth in the global infectious disease testing market. According to WHO, TB caused 1.25 million deaths in 2023, making it the world's leading infectious killer, surpassing COVID-19. With an estimated 10.8 million people falling ill globally, including many with drug-resistant TB, the demand for early, accurate, and accessible diagnostic testing continues to rise. The persistent emergence and re-emergence of infectious diseases have heightened the demand for accurate and timely diagnostic solutions. Outbreaks of diseases like COVID-19, Ebola, Zika, and antibiotic-resistant bacterial infections have underscored the need for rapid and efficient testing methods to detect, track, and manage these diseases. The globalization of travel and trade has facilitated the rapid spread of infectious agents across borders, making early detection and containment crucial to prevent outbreaks. This has driven up the demand for robust infectious disease testing infrastructure, including diagnostic assays, testing equipment, and surveillance systems.

The aging global population is more susceptible to infectious diseases, particularly due to compromised immune systems. As a result, there is a heightened focus on early detection and monitoring of infections in elderly individuals, contributing to market growth.

The rising awareness among healthcare professionals and the general public about the importance of early diagnosis and prompt treatment has also fueled demand. Timely infectious disease testing not only aids in better patient care but also helps in preventing the spread of diseases within communities. The increasing prevalence of infectious diseases, coupled with the need for rapid and accurate diagnosis, has led to substantial growth in the global infectious disease testing market. As infectious disease threats continue to evolve, the market is expected to further expand, with ongoing advancements in testing technologies and increased investment in public health infrastructure playing pivotal roles in addressing these global health challenges.

Key Market Challenges

Inadequate Reimbursements

Inadequate reimbursements within healthcare systems can indeed have a negative impact on the demand for global infectious disease testing. Reimbursements play a critical role in healthcare economics, affecting both healthcare providers and patients. When reimbursement rates for infectious disease testing are insufficient, healthcare providers, including hospitals, clinics, and laboratories, may struggle to cover the costs associated with testing. This financial strain can lead to reduced investment in testing infrastructure, limited availability of testing services, and even closures of diagnostic facilities in underserved areas.

Inadequate reimbursement rates can deter healthcare providers from offering a comprehensive range of infectious disease testing services. This may result in reduced access to critical diagnostic tests, leaving patients with limited options for early disease detection and management. Lower reimbursement rates can discourage laboratories and diagnostic companies from investing in research and development to improve testing accuracy, speed, and accessibility. This can stifle innovation and hinder the development of more advanced and cost-effective testing solutions. Reduced access to infectious disease testing due to inadequate reimbursements can exacerbate healthcare disparities, disproportionately affecting underserved populations. These disparities can result in delayed diagnoses and poorer health outcomes in vulnerable communities.

Key Market Trends

Point-of-Care Testing (POCT)

POCT devices that offer rapid results and can be used outside traditional healthcare settings will continue to gain popularity. They are especially valuable in resource-limited and remote areas. POCT devices are designed to be user-friendly and portable, making them accessible even in areas with limited healthcare infrastructure. They can be used in remote clinics, field hospitals, and rural communities, bringing essential diagnostic capabilities closer to patients.

In resource-limited and remote areas, access to centralized laboratories for traditional testing can be challenging. POCT devices offer the advantage of providing immediate results, allowing healthcare providers to diagnose and initiate treatment promptly. This is crucial for managing infectious diseases effectively and preventing their spread. Rapid results from POCT devices mean that patients do not have to wait for days or weeks to receive their test results. This helps alleviate anxiety, enables timely medical decisions, and improves patient satisfaction. POCT devices often require lower initial investments compared to establishing and maintaining a fully equipped laboratory. This cost-effectiveness is particularly valuable for healthcare facilities with limited budgets.

Key Market Players

• Biomerieux SA
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quidel Corporation
• Trinity Biotech PLC

Report Scope:

In this report, the Global Infectious Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infectious Disease Testing Market, By Product & Service:

• Assays
• Kits
• Reagents
• Instruments
• Services & Software

Infectious Disease Testing Market, By Technology:

• Molecular Diagnostics
• Immunoassay
• Microbiology
• Others

Infectious Disease Testing Market, By Disease:

• Hepatitis
• Human Papillomavirus (HPV)
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Hospital-Acquired Infections (HAIs)
• Others

Infectious Disease Testing Market, By End User:

• Hospital and Clinical Laboratories
• Diagnostic Reference Laboratories
• Academic/Research Institutes
• Others

Infectious Disease Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infectious Disease Testing Market.

Available Customizations:

Global Infectious Disease Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infectious Disease Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Assays, Kits, Reagents, Instruments, Services & Software)
  • 5.2.2. By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others)
  • 5.2.3. By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others)
  • 5.2.4. By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Infectious Disease Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Technology
  • 6.2.3. By Disease
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Infectious Disease Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Disease
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Infectious Disease Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Disease
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Infectious Disease Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Disease
      • 6.3.3.2.4. By End User

7. Europe Infectious Disease Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Technology
  • 7.2.3. By Disease
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Infectious Disease Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Disease
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Infectious Disease Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Disease
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Infectious Disease Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Disease
      • 7.3.3.2.4. By End User
  • 7.3.4. France Infectious Disease Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Disease
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Infectious Disease Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Disease
      • 7.3.5.2.4. By End User

8. Asia-Pacific Infectious Disease Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Technology
  • 8.2.3. By Disease
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Infectious Disease Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Disease
      • 8.3.1.2.4. By End User
  • 8.3.2. India Infectious Disease Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Disease
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Infectious Disease Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Disease
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Infectious Disease Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Disease
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Infectious Disease Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Disease
      • 8.3.5.2.4. By End User

9. South America Infectious Disease Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Technology
  • 9.2.3. By Disease
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Infectious Disease Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Disease
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Infectious Disease Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Disease
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Infectious Disease Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Disease
      • 9.3.3.2.4. By End User

10. Middle East and Africa Infectious Disease Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Technology
  • 10.2.3. By Disease
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Infectious Disease Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Disease
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Infectious Disease Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Disease
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Infectious Disease Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Disease
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Infectious Disease Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Biomerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. Danaher Corporation
• 15.6. F. Hoffmann-La Roche AG
• 15.7. Siemens Healthineers AG
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. Quidel Corporation
• 15.10. Trinity Biotech PLC

16. Strategic Recommendations

17. About Us & Disclaimer